Related Experiment Video

Updated: Mar 27, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in

Jovylyn G Gasendo1, Stacia Chan1, Hetika V Patel1

  • 1Kura Oncology, Inc., San Diego, California.

Molecular Cancer Therapeutics
|March 25, 2026
PubMed

Insights

A novel farnesyl transferase inhibitor (FTI), KO-2806, enhances anti-VEGFR tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) models. This combination therapy improves durability and overcomes resistance, offering new hope for advanced RCC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Anti-angiogenic tyrosine kinase inhibitors (TKIs) targeting VEGFR are standard for advanced renal cell carcinoma (RCC).
  • Limited response durability and acquired resistance necessitate novel therapeutic strategies.
  • There is a critical need for agents that enhance TKI efficacy and overcome resistance in RCC.

Purpose of the Study:

  • To investigate the potential of farnesyl transferase inhibitor (FTI) KO-2806 as a sensitizer to anti-VEGFR TKIs in RCC.
  • To determine if KO-2806 can enhance anti-angiogenic effects and overcome TKI resistance in preclinical RCC models.

Main Methods:

  • Preclinical models of renal cell carcinoma were treated with a combination of anti-VEGFR TKIs and KO-2806.
  • Inhibition of mTORC1 signaling in endothelial cells by KO-2806 was assessed.
  • Tumor neovascularization and regression were evaluated in response to combination therapy.

Main Results:

  • KO-2806 inhibits mTORC1 signaling in endothelial cells, augmenting the anti-angiogenic activity of TKIs.
  • Combination therapy with KO-2806 and anti-VEGFR TKIs resulted in significant tumor regressions.
  • Tumor neovascularization was robustly inhibited by the combination treatment.
  • KO-2806 demonstrated efficacy in sensitizing tumors that had progressed on prior TKI therapy.

Conclusions:

  • KO-2806 enhances the anti-angiogenic effects of VEGFR TKIs by inhibiting endothelial cell mTORC1 signaling.
  • The combination of KO-2806 with anti-VEGFR TKIs shows promise for treating advanced RCC, including in cases of acquired resistance.
  • KO-2806 represents a potential therapeutic partner to improve treatment outcomes across the RCC treatment continuum.

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

628
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
67
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
633
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.8K